These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 28755993)

  • 21. Targeting glioblastoma cancer stem cells: the next great hope?
    Khan IS; Ehtesham M
    Neurosurg Focus; 2014 Dec; 37(6):E7. PubMed ID: 25581936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Personalized therapy and stem cell transplantation for pro-inflammatory modulation of cancer stem cells microenvironment in glioblastoma: Review.
    Bryukhovetskiy I; Pak O; Khotimchenko Y; Bryukhovetskiy A; Sharma A; Sharma HS
    Int Rev Neurobiol; 2020; 151():67-98. PubMed ID: 32448615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanoparticles for hyperthermic therapy: synthesis strategies and applications in glioblastoma.
    Verma J; Lal S; Van Noorden CJ
    Int J Nanomedicine; 2014; 9():2863-77. PubMed ID: 24959075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent Advances in Immune Cell Therapy for Glioblastoma.
    Kang X; Zheng Y; Hong W; Chen X; Li H; Huang B; Huang Z; Tang H; Geng W
    Front Immunol; 2020; 11():544563. PubMed ID: 33193310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.
    Bambury RM; Morris PG
    Expert Rev Anticancer Ther; 2014 Aug; 14(8):955-64. PubMed ID: 24814143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions.
    Corso CD; Bindra RS
    Semin Radiat Oncol; 2016 Oct; 26(4):281-98. PubMed ID: 27619250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in immunotherapy for the treatment of glioblastoma.
    Tivnan A; Heilinger T; Lavelle EC; Prehn JH
    J Neurooncol; 2017 Jan; 131(1):1-9. PubMed ID: 27743144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment
    Yang J; Shi Z; Liu R; Wu Y; Zhang X
    Theranostics; 2020; 10(7):3223-3239. PubMed ID: 32194864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy targeting glioma stem cells--insights and perspectives.
    Li Z; Lee JW; Mukherjee D; Ji J; Jeswani SP; Black KL; Yu JS
    Expert Opin Biol Ther; 2012 Feb; 12(2):165-78. PubMed ID: 22200324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques.
    Czarnywojtek A; Borowska M; Dyrka K; Van Gool S; Sawicka-Gutaj N; Moskal J; Kościński J; Graczyk P; Hałas T; Lewandowska AM; Czepczyński R; Ruchała M
    Pharmacology; 2023; 108(5):423-431. PubMed ID: 37459849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New Directions in the Treatment of Glioblastoma.
    Reitman ZJ; Winkler F; Elia AEH
    Semin Neurol; 2018 Feb; 38(1):50-61. PubMed ID: 29548052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma.
    Kievit FM; Wang K; Ozawa T; Tarudji AW; Silber JR; Holland EC; Ellenbogen RG; Zhang M
    Nanomedicine; 2017 Oct; 13(7):2131-2139. PubMed ID: 28614736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of nanoparticles for glioblastoma treatment: a new approach.
    Játiva P; Ceña V
    Nanomedicine (Lond); 2017 Oct; 12(20):2533-2554. PubMed ID: 28952878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemoresistance in high-grade gliomas: relevance of adenosine signalling in stem-like cells of glioblastoma multiforme.
    Garrido W; Rocha JD; Jaramillo C; Fernandez K; Oyarzun C; San Martin R; Quezada C
    Curr Drug Targets; 2014; 15(10):931-42. PubMed ID: 25174341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles.
    Cohen ZR; Ramishetti S; Peshes-Yaloz N; Goldsmith M; Wohl A; Zibly Z; Peer D
    ACS Nano; 2015 Feb; 9(2):1581-91. PubMed ID: 25558928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: Current status with an emphasis on delivery systems.
    Mirzaei S; Mahabady MK; Zabolian A; Abbaspour A; Fallahzadeh P; Noori M; Hashemi F; Hushmandi K; Daneshi S; Kumar AP; Aref AR; Samarghandian S; Makvandi P; Khan H; Hamblin MR; Ashrafizadeh M; Zarrabi A
    Life Sci; 2021 Jun; 275():119368. PubMed ID: 33741417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of glioblastoma (GBM) molecular classification methods.
    Lee E; Yong RL; Paddison P; Zhu J
    Semin Cancer Biol; 2018 Dec; 53():201-211. PubMed ID: 30031763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.